RxNews Recap for 08-23-10 Print E-mail
By Mary Davila   
Monday, 23 August 2010 17:40
Below is a list of the companies that made news in the healthcare sector on Monday, August 23, 2010.

Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.

AdvanSource Biomaterials Corporation (NYSE Amex: ASB), a leading developer, manufacturer and seller of advanced polymer technologies and materials for a broad range of medical devices, today announced it was notified by the staff of the NYSE Amex that a review of the Company’s Form 10-Q for the period ended June 30, 2010 indicated that the Company is not in compliance with one of the NYSE Amex’s continued listing standards as set forth in Part 10 of the NYSE Amex’s Company Guide (the “Company Guide”).

Agilent Technologies Inc. (NYSE: A) announced Martin Karplus, professor emeritus, Department of Chemistry and Chemical Biology, Harvard University; and Laboratoire de Chimie Biophysique, ISIS, Université Louis Pasteur, the winner of the 2010 Russell Varian Prize.

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN)
today announced that the US Food and Drug Administration (FDA) has approved Alexion’s Rhode Island manufacturing facility (ARIMF) in Smithfield, Rhode Island as a second source of commercial supply for Soliris® (eculizumab).

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and collaborators at The Parkinson’s Institute and the Mayo Clinic have published new research findings in the journal Public Library of Science (PLoS).

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced the publication online in Nature Medicine of new preclinical data demonstrating that AVI-6002 and AVI-6003, the respective lead therapeutic candidates against Ebola and Marburg viruses, both employing AVI's advanced PMOplus™ chemistry, provide post exposure efficacy in non-human primates.

Biomerica, Inc. (OTCBB: BMRA) announced today that it has introduced a new 15 minute consumer home test to determine allergy to dogs.

Diagnostic Imaging International Corp. (OTCBB:DIIG) ( DIIG"), owns and operates CTS, a Teleradiology company, announced today its financial results for the three- months ended June 30, 2010.

Cindy Morrissey, President and CEO of Emerging Healthcare Solutions, Inc. (Pink Sheets: EHSI), called the results of a recent study on Friday an ‘encouraging step’ towards the use of stem cells to regenerate human organs.

Encorium Group, Inc. (Nasdaq:ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that it intends to commence a rights offering for up to 3,401,151 shares of its common stock.

EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) today announced that it received a refusal to file letter from the U.S. Food and Drug Administration (FDA) on the New Drug Application (NDA) for Ceplene® (histamine dihydrochloride)

GeckoSystems Intl. Corp. (PINKSHEETS: GCKO) announced today that its stock is now quoted in the U.S. over-the-counter (OTC) markets, on the Pink Sheets "Current Information" tier, under the ticker symbol GCKO.GeckoSystems is a dynamic leader in the emerging mobile robotics industry revolutionizing their development and usage with "Mobile Robot Solutions for Safety, Security and Service™."

Genzyme Corporation (NASDAQ: GENZ) announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood.

Hop-on (PINKSHEETS: HPNN) and USAcig -- Rush Limbaugh recently cited electric cigarettes for his immediate success in his quest to stop smoking tobacco products.

Huifeng Bio-Pharmaceutical Technology, Inc. (OTC Bulletin Board:HFGB), specializing in developing and producing botanical extracts and other raw materials for pharmaceuticals and food additives today reiterated its financial results for its second quarter ended June 30, 2010.

Humana Inc. (NYSE: HUM) and Availity, LLC today announced the deployment of CarePrescribe, an electronic prescribing service, at no charge to eligible physician practices in Kentucky.

Imagenetix, Inc. (OTC Bulletin Board:IAGX) announced today that based on solid bookings and sales activities in July and the first half of August that it expects its net sales for its second quarter of fiscal 2011 ending September 30, 2010, to be from $2.8 to $3.2 million, an increase of 158% to 195% compared to the first quarter of fiscal 2011 and 47% to 68% compared to the second quarter of the previous fiscal year.

InSite Vision Incorporated (OTCBB:INSV), a company developing novel ophthalmic therapeutics, today announced the initiation of a Phase 1/2 clinical trial of ISV-303, a topical anti-inflammatory product intended to reduce the pain and inflammation associated with ocular surgery.

Kendle (Nasdaq:KNDL), a leading, global full-service clinical research organization, today announced the appointment of Jeffrey M. Zucker as Senior Director and Global Head, Patient Recruitment.  

Kensey Nash Corporation (Nasdaq:KNSY), a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its three months and fiscal year ended June 30, 2010.

Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today the nationwide availability of a genetic test to detect the presence of a single polymorphism within the IL-28B gene that has been reported to help predict a person’s response to certain hepatitis C virus (HCV) therapies.

Life Technologies Corporation (NASDAQ: LIFE) today announced that its Applied Biosystems™ 3500 Dx Series Genetic Analyzers, the first CE IVD-marked capillary electrophoresis system for nucleic acid analysis, are now available for sale in Australia, India, New Zealand, Singapore, and Taiwan.

MannKind Corporation (Nasdaq: MNKD) today announced that the company will supply its novel, ultra rapid acting insulin AFREZZATM (insulin human [rDNA origin]) for use in a study being conducted by the Juvenile Diabetes Research Foundation (JDRF) as part of its Artificial Pancreas Project.

Metiscan, Inc., (PINKSHEETS:MTIZ) publicly traded under the ticker symbol (PINKSHEETS:MTIZ), announced today that the Company has filed its Registration Statement on Form S-1 with the Securities and Exchange Commission (SEC).

NanoLogix, Inc. (PINKSHEETS: NNLX) The U.S. Environmental Protection Agency announced it has entered into a Cooperative Research and Development Agreement (CRADA) with NanoLogix.The Agency and NanoLogix will work to design a rapid diagnostic method to detect bacterial threats, including E.coli and Cryptosporidium in drinking and source water. Scientists from the EPA and NanoLogix will use the company's rapid detection technology as a foundation for the new process, with the goal of significantly reduced test times from those achievable with current tests.

NexMed, Inc. (Nasdaq: NEXM), backed by a revenue generating CRO business and seeking to leverage its proprietary, multi-route NexACT® drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, today announced that the Israel Patent Office has issued an allowance notice for NexMed’s patent application entitled, “Topical Compositions for Prostaglandin E1 Delivery.”

Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Care360™ Electronic Health Record (EHR), Version 2010.1, has been inspected by the Certification Commission for Health Information Technology (CCHIT®) and is a certified EHR Module, IFR Stage 1, achieving all 14 of the requirements applied for of the 24 requirements for Eligible Providers published by the U.S. Department of Health and Human Services (HHS) in the Interim Final Rule of January 2010.

Soligenix, Inc. (OTC Bulletin Board:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today that it has been awarded a three year $1.2 million clinical research grant by the Office of Orphan Products Development (OOPD) of the U.S. Food and Drug Administration (FDA) pursuant to its Orphan Products Development (OPD) Program.

Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” Pink Sheets: TAROF) today provided preliminary, unaudited and unreviewed information on its financial performance for the first half of 2010.

Wave Systems Corp. (NASDAQ: WAVX) (http://www.wave.com) today announced that Boston Medical Center's Network Security Engineer Mark Mulvaney will share his insights on the need for encryption in hospitals and discuss the fundamental differences between software- and hardware-based encryption.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus